Literature DB >> 24811298

The composition and metabolism of large and small LDL.

Margaret R Diffenderfer1, Ernst J Schaefer.   

Abstract

PURPOSE OF REVIEW: Decreased size and increased density of LDL have been associated with increased coronary heart disease (CHD) risk. Elevated plasma concentrations of small dense LDL (sdLDL) correlate with high plasma triglycerides and low HDL cholesterol levels. This review highlights recent findings about the metabolism and composition of LDL subfractions. RECENT
FINDINGS: The development of an automated assay has recently made possible the assessment of the CHD risk associated with sdLDL in large clinical trials and has demonstrated convincingly that sdLDL cholesterol levels are a more significant independent determinant of CHD risk than total LDL cholesterol. Metabolic studies have revealed that sdLDL particles originate through the delipidation of larger atherogenic VLDL and large LDL and from direct de novo production by the liver. Proteins associated with LDL, in addition to apolipoprotein (apo) B, include the C apolipoproteins, apoA-I, apoA-IV, apoD, apoE, apoF, apoH, apoJ, apoL-1, apoM, α-1 antitrypsin, migration inhibitory factor-related protein 8, lysosome C, prenylcysteine oxidase 1, paraoxonase 1, transthyretin, serum amyloid A4, and fibrinogen α chain. The role of the increasing number of LDL-associated proteins remains unclear; however, the data do indicate that LDL particles not only transport lipids but also carry proteins involved in inflammation and thrombosis. The sdLDL proteome in diabetic individuals differs significantly from that of larger LDL, being enriched in apoC-III.
SUMMARY: Progress in our understanding of the composition and metabolism of LDL subfractions strengthens the association between sdLDL and CHD risk.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24811298     DOI: 10.1097/MOL.0000000000000067

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  40 in total

1.  Association of rheumatoid arthritis disease activity and antibodies to periodontal bacteria with serum lipoprotein profile in drug naive patients.

Authors:  Aulikki Kononoff; Pia Elfving; Pirkko Pussinen; Sohvi Hörkkö; Hannu Kautiainen; Leena Arstila; Leena Laasonen; Elina Savolainen; Helena Niinisalo; Jarno Rutanen; Olga Marjoniemi; Mari Hämäläinen; Katriina Vuolteenaho; Eeva Moilanen; Oili Kaipiainen-Seppänen
Journal:  Ann Med       Date:  2020-02-10       Impact factor: 4.709

Review 2.  Structural stability and functional remodeling of high-density lipoproteins.

Authors:  Olga Gursky
Journal:  FEBS Lett       Date:  2015-03-05       Impact factor: 4.124

3.  LDL subclass lipidomics in atherogenic dyslipidemia: effect of statin therapy on bioactive lipids and dense LDL.

Authors:  M John Chapman; Alexina Orsoni; Ricardo Tan; Natalie A Mellett; Anh Nguyen; Paul Robillard; Philippe Giral; Patrice Thérond; Peter J Meikle
Journal:  J Lipid Res       Date:  2020-04-15       Impact factor: 5.922

Review 4.  Hepatitis C virus relies on lipoproteins for its life cycle.

Authors:  Germana Grassi; Giorgia Di Caprio; Gian Maria Fimia; Giuseppe Ippolito; Marco Tripodi; Tonino Alonzi
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

Review 5.  Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats.

Authors:  O Guttman; B M Baranovski; R Schuster; Z Kaner; G S Freixo-Lima; N Bahar; N Kalay; M I Mizrahi; I Brami; D E Ochayon; E C Lewis
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

6.  Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia: effects of rosuvastatin.

Authors:  Nuntakorn Thongtang; Margaret R Diffenderfer; Esther M M Ooi; P Hugh R Barrett; Scott M Turner; Ngoc-Anh Le; W Virgil Brown; Ernst J Schaefer
Journal:  J Lipid Res       Date:  2017-04-09       Impact factor: 5.922

Review 7.  Assessing cardiovascular risk in hepatitis C: An unmet need.

Authors:  Javier Ampuero; Manuel Romero-Gómez
Journal:  World J Hepatol       Date:  2015-09-08

Review 8.  Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.

Authors:  Nicola Ferri; Massimiliano Ruscica
Journal:  Endocrine       Date:  2016-04-01       Impact factor: 3.633

Review 9.  Deepening our understanding of HDL proteome.

Authors:  Graziella Eliza Ronsein; Tomáš Vaisar
Journal:  Expert Rev Proteomics       Date:  2019-08-27       Impact factor: 3.940

Review 10.  Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials.

Authors:  Alberico Luigi Catapano; Angela Pirillo; Giuseppe Danilo Norata
Journal:  Br J Pharmacol       Date:  2017-05-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.